More data from Lilly's Phase III baricitinib study released

16 February 2017
lilly-incyte-big

Eli Lilly (NYSE: LLY) and Incyte Corp (Nasdaq: INCY) have published new, more detailed results from a pivotal study of baricitinib in the New England Journal of Medicine.

The American companies are co-developing the drug, an oral selective JAK1 and JAK2 inhibitor, for the treatment of moderate-to-severe rheumatoid arthritis (RA).

The data show that a higher proportion of patients taking baricitinib, compared to Humira (adalimumab), achieved a statistically-significant improvement in multiple components of RA disease activity.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical